News

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023. The 2023

Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for

Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with

Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics, Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program

VITAS Healthcare Corporation, a wholly-owned subsidiary of Chemed Corporation (“Chemed”) (NYSE: CHE), announced it entered into an agreement on March 12, 2024 to acquire all hospice operations and

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 26^th Annual Global Healthcare Conference on Wednesday, March 13^th, at 10:15 a.m. ET

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the Barclays 26th Annual Global Healthcare Conference, which is being held March 12 - 14, 2024, in

Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3)

Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 34th Annual Healthcare Conference on Tuesday, March 12, 2024, at approximately 12:00

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in a fireside chat at the Barclays

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the Raymond James 45^th Annual Institutional Investors Conference, which is being held March 3 - 6

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company

Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for

Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2023.

Fourth Quarter Highlights

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023. Novocure is a global oncology company working to extend survival in some of the most

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO)

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the

Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 40-cents per share on the Company’s capital stock, payable on March 15, 2024, to

PINC AI^™, the technology and services brand of Premier, Inc. (NASDAQ: PINC), today announced the nation’s 50 Top Cardiovascular Hospitals^™. The full list of recognized hospitals was published in an

Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the fourth quarter ended December 31, 2023, on Tuesday, February 27, 2024, following the close of trading

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2023 and provided guidance for 2024. For the quarter, revenue was $1.01

PINC AI™ Applied Sciences (PAS), a division of Premier, Inc. (NASDAQ: PINC), and Datavant, the company that protects, connects and delivers the world’s health data, announce the companies are

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its fourth quarter and year-end 2023 results on Tuesday, February 27, 2024, after the close of the market. Acadia